



NDA 22150/S-004

**SUPPLEMENT APPROVAL  
FULFILLMENT OF POSTMARKETING  
REQUIREMENT**

Shire Human Genetic Therapies  
300 Shire Way  
Lexington, MA 02421

Attention: Thomas Class, RAC  
Group Director, Regulatory Affairs

Dear Mr. Class:

Please refer to your Supplemental New Drug Application (sNDA) dated April 30, 2013, received April 30, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Firazyr® (icatibant acetate) Injection.

We acknowledge receipt of your amendments dated August 15 and 29, 2013.

This “Prior Approval” supplemental new drug application proposes to include the results of the 104-week rat carcinogenicity study of icatibant acetate injection (study JE049-0162) into Section 13.1 of the Package Insert.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### **FULFILLMENT OF POSTMARKETING REQUIREMENT**

We refer to your submission dated June 14, 2012, containing the final report for the following postmarketing requirement listed in the August 25, 2011, approval letter.

1810-2 Submit the results of your ongoing 104-week rat carcinogenicity study of icatibant acetate injection.

We also refer to our letter dated March 22, 2013, requesting that you submit a labeling supplement to update the labeling in Section 13.1 to include the results of the 2-year rat carcinogenicity study with icatibant. This prior approval labeling supplement addresses our request for a labeling supplement.

We have reviewed your submission and conclude that the above requirement was fulfilled.

We remind you that there is a postmarketing requirement listed in the August 25, 2011, approval letters that is still open.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Colette Jackson, Senior Regulatory Project Manager, at (301) 796-1230.

Sincerely yours,  
*{See appended electronic signature page}*

Sally Seymour, M.D.  
Deputy Director for Safety  
Division of Pulmonary, Allergy, and Rheumatology  
Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

ENCLOSURE(S):  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

SALLY M SEYMOUR  
08/30/2013